A REVIEW ON NOVEL ORAL ANTICOAGULANTS ROLE IN PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM COMPLICATIONS IN CLINICAL SETTINGS
S. Aishwarya*, B. Mothishwaran and S. Uma
Abstract
Venous thromboembolism (VTE) which consists principally of deep
vein thrombosis (DVT) and pulmonary embolism (PE) is a common
cause of morbidity and mortality. Venous thromboembolism (VTE),
which includes DVT and pulmonary embolism (PE), affects 1 per
1,000 people and contributes to 60,000–100,000 deaths annually.
Normal blood physiology depends on a delicate balance between proand
anti-coagulant factors. Virchow’s Triad distills the multitude of
risk factors for DVT into three basic elements favoring thrombus
formation includes venous stasis, vascular injury, and
hypercoagulability. Clinical, biochemical, and radiological
examinations are used to detect the incidence of deep vein thrombosis
in the community. Deep venous thrombosis is a life threatening condition. Administration of
oral anticoagulants can lower the future occurrence of disease complications. Early
assessment of an individual patient’s risk factors, clinical history, interacting medications,
can enhance the therapeutic outcomes of individuals. Novel drugs for the treatment of deep
vein thrombosis include the direct factor Xa inhibitors, rivaroxaban, apixaban can prevent the
future occurrence of deep vein thrombosis complications in the society.
Keywords: Venous thromboembolism, pulmonary embolism, venous stasis, vascular injury, anti-coagulants.
[Full Text Article]